Revolution Medicines used the ASCO 2026 plenary to deliver detailed Phase 3 results for daraxonrasib (RASolute 302) in previously treated, metastatic pancreatic ductal adenocarcinoma. The pan-RAS inhibitor extended overall survival versus standard chemotherapy, including a strong effect in RAS G12-mutant patients, with the dataset published in The New England Journal of Medicine. Across the full study population, the updated disclosures showed a sizable survival separation and longer disease control measures, shifting the competitive narrative for second-line pancreatic cancer. The presentation also reinforced a mutation-agnostic benefit pattern, narrowing the gap between biomarker-selected and broader use cases. For developers and investors, the readout raises the probability of rapid clinical and regulatory momentum in RAS-driven PDAC, particularly given the continued need for more durable therapies after first-line failure. Separately, an ASCO roundup reiterated how the “landscape-changing” survival curve is being framed by oncology experts, highlighting daraxonrasib’s potential to define a new standard in an area where historic gains have been incremental.